Mepolizumab
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
- Mepolizumab
- Mepolizumab: From Anti-IL-5 Biologic (Nucala) to Thrombocytopenia Due to Immune Destruction
Mepolizumab: From Anti-IL-5 Biologic (Nucala) to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Mepolizumab is an anti-IL-5 antibody that depletes eosinophils and is marketed in the US as Nucala. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, but only 1 case report supports this and there are no registered clinical trials. The high score comes from graph-based prediction and is not clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 license entries (2 unique BLAs: BLA125526, BLA761122) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Mepolizumab is an anti-IL-5 antibody that depletes eosinophils. Detailed mechanism of action data is not available in the current dataset. The reasoning below rests on the antibody’s known target.
The only link to immune-mediated low platelet counts is indirect. A benefit would most likely come from controlling eosinophil-driven immune dysregulation, not from any direct effect on platelet destruction. The single supporting paper is a case report of a steroid-resistant hypereosinophilic immune diathesis with a concomitant mixed thrombotic microangiopathy. The available excerpt does not confirm a platelet outcome or separate the effect of mepolizumab from other concomitant therapy.
The very high TxGNN score (0.997) reflects proximity in the knowledge graph. It should be treated as a research question, not as evidence of efficacy.
The other four predictions are weaker still:
- Autoimmune thrombocytopenic has a theoretical Th2/eosinophil rationale but no evidence. It overlaps the top prediction and is not independent support.
- Primary release disorder of platelets cites only a hypereosinophilic syndrome review that does not address platelet function.
- Pseudo-von Willebrand disease and Glanzmann thrombasthenia have no plausible link to IL-5 blockade and no trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case report | Blood Cells Mol Dis | Mepolizumab resolved a steroid-resistant hypereosinophilic immune diathesis, with concomitant improvement of a mixed thrombotic microangiopathy. Platelet outcome is not confirmed in the available excerpt. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA125526 | Nucala | Injection, powder, for solution | GlaxoSmithKline LLC |
| BLA761122 | Nucala | Injection, solution | GlaxoSmithKline LLC |
The pack lists BLA761122 twice with identical details, so it appears once here. Approved indication text is not available in the dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is one case report and no trials. The mechanistic link between IL-5 blockade and platelet destruction is indirect, and the prediction score alone cannot support development.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for each license, to establish the original indication
- Full-text review of PMID 28648630 to confirm the platelet outcome and any confounding therapy
- Any controlled or observational data on mepolizumab in immune thrombocytopenia, especially in patients with concurrent eosinophilia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.